SAROGLITAZAR

Written By:Sakshi Anil MoreB. Pharm Reviewed By:Dr. Tejashwin AdigaMBBS

Last updated on 31 Mar 2026 | 09:31 AM (IST)

SAROGLITAZAR

Background and Date of approval SAROGLITAZAR

The U.S. FDA approved Saroglitazar for neurological disorders on February 13. Saroglitazar belongs to the medication class called dual peroxisome proliferator-activated receptor (PPAR) agonist. It works by managing high cholesterol and triglycerides, along with blood sugar levels in type 2 diabetes.

Uses of SAROGLITAZAR

Saroglitazar is used to treat diabetic dyslipidemia (an abnormal amount of lipids in the blood) and hypertriglyceridemia (high level of triglycerides in the blood) in patients with type 2 diabetes mellitus that is not controlled by statin therapy.

How is SAROGLITAZAR administered?

Take the Saroglitazar as your physician advises. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.

Side Effects of SAROGLITAZAR

The most common side effects of Saroglitazar are gastritis (stomach inflammation), nausea, vomiting, asthenia (weakness), chest discomfort, dizziness, fever, and weakness.

Warnings

Saroglitazar should not be consumed if you are allergic to Saroglitazar or any of its ingredients in the medication. Before using this medicine, let your doctor know if you have any liver or kidney problems or a history of muscle issues. If you have heart disease, be cautious as this medicine hasn't been studied in severe heart failure patients. Although uncommon, watch for rapid weight gain, which may be a sign of swelling and heart-related symptoms. If you experience any concerning symptoms, contact your doctor right away.

Precautions

Before starting the treatment, inform your doctor if you are pregnant, think you may be pregnant, or planning to get pregnant or breastfeeding. The safety and effectiveness of Saroglitazar have not been confirmed for use in children. Patients with liver, heart, and kidney conditions should take Saroglitazar cautiously and should inform the doctor about all the underlying medical conditions.

Word of Advice

Do not stop the medicine until your doctor advises. Do not double-dose the medicine to make up for a forgotten dose. Notify your doctor if you experience any serious side effects. Your medical professional will inform you if you need any dose adjustments. Contact your doctor for more information. Keep out of sight and reach of pets and children. Do not freeze the medicine. Always check the expiry date before consuming it.

Frequently Asked Questions

Q1.

How to manage the side effects of Saroglitazar?

To manage the side effects of Saroglitazar, follow the prescribed dosage and report side effects promptly. To lower the risk of additional liver damage, maintain a healthy diet and exercise regularly. Monitor your liver function with routine blood tests. If you experience any liver-related pain or discomfort, consult your doctor for guidance.

Q2.

What are the side effects of Saroglitazar?

Common side effects of Saroglitazar include gastritis (stomach inflammation), nausea, vomiting, asthenia (weakness), chest discomfort, dizziness, fever, and weakness. It is crucial to consult your doctor for any concerns or persistent side effects.

Q3.

Can you take Saroglitazar when pregnant?

Limited information is available on using Saroglitazar during pregnancy. So consult your medical professional regarding the usage. The potential benefits and risks should be carefully assessed. Your doctor will suggest taking this medicine only if it's necessary.

Q4.

What should I do if I miss a dose of Saroglitazar?

If you miss a dose of the medicine, take it as soon as possible. However, if it's close to the time for your next dose, skip the missed dose and continue with your regular schedule. Do not double the dose of the Saroglitazar.

Q5.

What is Saroglitazar used for?

Saroglitazar is an antidiabetic drug used to treat diabetic dyslipidemia and hypertriglyceridemia in individuals with Type 2 diabetes mellitus, especially when statin therapy is ineffective in controlling these conditions.

References

Saroglitazar; [Accessed 20th July 2023]; lipaglyn.com/downloads/Lipaglyn_PI_Booklet.pdf
Clinical trials, [Accessed 20th July 2023] https://www.clinicaltrialsarena.com/projects/lipaglyn-saroglitazar-treating-type-ii-diabetes/

Disclaimer

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.

;